Kodiak Sciences reported positive phase III Glow2 (tarcocimab tedromer), setting up an accelerated multi-indication BLA path for the newly branded Zenkuda in diabetic retinopathy. The topline results showed a large separation versus sham, with 62.5% of treated patients achieving at least a two-step improvement in DR severity score compared with 3.3% on sham. The readout arrives after investor caution tied to earlier setbacks and now reframes Kodiak’s ocular strategy around an antibody biopolymer conjugate formulation approach. Kodiak also positioned Glow2 as the first of multiple phase III catalysts expected through the year, with implications for how its IL-6/VEGF-focused bispecific programs may translate into clinical outcomes.